Imatinib-induced long-term remission in a relapsed RCSD1-ABL1-positive acute lymphoblastic leukemia

The treatment of patients with BCR-ABL1 -positive chronic myeloid leukemia and acute lymphoblastic leukemia (ALL) with tyrosine kinase inhibitors (TKIs) has significantly improved their overall survival.[1][1]–[3][2] Several reports confirm that this type of treatment may be similarly effective